Fagron solidifies its leadership position with the acquisition of Guinama in Spain

Group 1 - Fagron has acquired Guinama in Spain, reinforcing its leadership in the pharmaceutical compounding market [1][2] - Guinama specializes in repackaging and distribution of active pharmaceutical ingredients and excipients, enhancing Fagron's competitive position in the Iberian market [2] - The enterprise value of the acquisition is approximately €22 million, with Guinama generating low double-digit millions in annual revenue and an EBITDA margin slightly above Fagron's existing group margin [3] Group 2 - The acquisition aligns with Fagron's strategic growth approach, aiming to optimize sourcing, streamline operations, and centralize warehousing [4] - Fagron operates in over 30 countries, focusing on personalized medicine for hospitals, pharmacies, clinics, and patients [4] - The company is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [5]